Heron Therapeutics (HRTX) Non-Current Deffered Revenue (2010)
Heron Therapeutics (HRTX) reported Non-Current Deffered Revenue of $35000.0 for Q4 2010.
Heron Therapeutics (HRTX) Non-Current Deffered Revenue (2010) Analysis & Trends
Heron Therapeutics has reported Non-Current Deffered Revenue for 1 years, with the latest figure at $35000.0 in Q4 2010.
- For the quarter ending Q4 2010, Non-Current Deffered Revenue changed N/A year-over-year to $35000.0; the trailing twelve-month figure through Dec 2010 stood at $35000.0 (changed N/A YoY), and the FY2010 full-year result was $35000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q4 2010 stood at $35000.0.
- The five-year high for Non-Current Deffered Revenue was $35000.0 in Q4 2010, with the low at $35000.0 in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Heron Therapeutics | 85.57 Mn | 55.60 Mn | 24.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 35,000.00 |